Instrument Inactif

Communiqués Aviragen Therapeutics Inc Nasdaq

Actions

US0906941002

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

08/07	HilleVax interrompt le développement de son vaccin contre le norovirus pour les nourrissons ; les actions s'effondrent	RE
14/06	Mise à jour sectorielle : Les actions du secteur de la santé sont en baisse avant la cloche de vendredi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vaxart Provides Business Update	17/06	AQ
Vaxart Announces $40 Million Underwritten Offering of Common Stock	14/06	AQ
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	13/06	AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23/05	AQ
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results	13/05	AQ
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13	07/05	AQ
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers	30/04	AQ
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	27/03	AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/03	AQ
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	14/03	AQ
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	07/03	AQ
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	06/03	AQ
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	05/02	AQ
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	19/01	AQ
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	16/01	AQ
Vaxart, Inc. Announces Management Change	16/01	AQ
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	21/12	AQ
Vaxart : Investor Presentation November 2023	02/11	PU
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results	02/11	AQ
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	02/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aviragen Therapeutics Inc Nasdaq

Actions

US0906941002

Communiqués

Filtres